NEW YORK (360Dx) – Proteomic diagnostics firm Prevencio has released a research-use-only version of its HART cardiovascular biomarker panels and is planning to launch laboratory-developed tests for predicting the presence of obstructive coronary artery disease (HART CAD) and predicting major adverse cardiac events (HART CVE) in either late 2018 or early 2019.

The company also this week presented data at the American Diabetes Association 2018 Scientific Sessions demonstrating that its HART CAD and HART CVE tests are as effective in diabetic patients as in patients without diabetes.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.